Claims for Patent: 10,450,361

Summary for Patent: 10,450,361

Title:	Methods related to CTLA4-Fc fusion proteins
Abstract:	The present disclosure provides, in part, methods for evaluating, identifying, and/or producing (e.g., manufacturing) a CTLA4-Fc fusion protein, e.g., abatacept. In some instances, methods herein allow highly resolved evaluation of abatacept useful for, inter alia, manufacturing abatacept, characterizing abatacept, identifying and/or confirming abatacept, monitoring the structure of abatacept, comparing abatacept preparations made over time or made under different conditions, and/or controlling the structure of abatacept.
Inventor(s):	Robblee; John (Cambridge, MA), He; Xiaomei (Cambridge, MA), Yin; Yan (Cambridge, MA), Lin; Yin Yin (Cambridge, MA), Collins; Brian (Cambridge, MA), Murphy; Jennifer (Cambridge, MA), Kaundinya; Ganesh (Cambridge, MA)
Assignee:	Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	14/404,939
Patent Claims:	1. A method of manufacturing an abatacept drug product, comprising: providing or obtaining a test glycoprotein preparation; acquiring a value for each of a plurality of parameters listed in Table 1 for the test glycoprotein preparation, wherein the values for the plurality of parameters in combination distinguish abatacept from a non-abatacept glycoprotein; and wherein the plurality of abatacept parameters comprise the percent aglycosylation at O129 and the percent aglycosylation at O139; and processing, or directing the processing of, at least a portion of the test glycoprotein preparation as abatacept drug product if the values for the plurality for the test glycoprotein preparation meet the corresponding reference criteria shown in Table 1 for said parameters, wherein the reference criteria include 36.2-59.3% aglycosylation at O129 and 0.8-2.7% aglycosylation at O139, or taking an alternative action if the values for the plurality of abatacept parameters for the test glycoprotein preparation do not meet the corresponding reference criteria shown in Table 1 for the parameters, including 36.2-59.3% aglycosylation at O129 and 0.8-2.7% aglycosylation at O139; thereby manufacturing an abatacept drug product, wherein the test glycoprotein preparation comprises a glycoprotein composition having an amino acid sequence with at least 98% identity to SEQ ID NO:1, and wherein amino acid 29 is alanine and amino acid 104 is leucine. 2. The method of claim 1, wherein the plurality of abatacept parameters comprises a total of: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or 54 of the abatacept parameters listed in Table 1. 3. The method of claim 1, wherein the test glycoprotein preparation has an amino acid sequence with 100% identity to SEQ ID NO: 1. 4. The method of claim 1, wherein the value is directly obtained by performing an analytical test on the test glycoprotein preparation. 5. The method of claim 4, wherein the value is directly obtained using a method provided in Table 7. 6. The method of claim 1, wherein the processing step comprises combining the test glycoprotein preparation with an excipient or buffer. 7. The method of claim 1, wherein the processing step comprises one or more of: formulating the test glycoprotein preparation; processing the test glycoprotein preparation into a drug product; combining the test glycoprotein preparation with a second component; changing the concentration of the glycoprotein in the preparation; lyophilizing the test glycoprotein preparation; combining a first and second aliquot of the glycoprotein to provide a third, larger, aliquot; dividing the test glycoprotein preparation into smaller aliquots; disposing the test glycoprotein preparation into a container; packaging the test glycoprotein preparation; associating a container comprising the test glycoprotein preparation with a label; and shipping or moving the test glycoprotein to a different location. 8. The method of claim 1, wherein the processed glycoprotein is approved under Section 351(k) of the Public Health Service (PHS) Act. 9. The method of claim 1, wherein the processed glycoprotein is not approved under a BLA under Section 351(a) of the PHS Act. 10. The method of claim 1, wherein the input value is acquired for one, two or more samples or batches. 11. The method of claim 1, wherein the input value(s) for the test glycoprotein preparation comprise an average of a range of values for the parameter for multiple batches or samples of the test glycoprotein. 12. The method of claim 1, wherein the plurality of the reference criteria shown in Table 1 are a specification for commercial release of an abatacept drug product under Section 351(k) of the Public Health Service Act. 13. The method of claim 1, comprising: providing a host cell that is genetically engineered to express a CTLA4-Fc fusion protein having an amino acid sequence with at least about 98% identity to SEQ ID NO:1, wherein amino acid 29 is alanine and amino acid 104 is leucine; culturing the host cell under conditions whereby the cell expresses the CTLA4-Fc fusion protein; and harvesting the CTLA4-Fc fusion protein from the host cell culture to produce a test glycoprotein preparation. 14. The method of claim 13, wherein: the host cell is genetically engineered to express glycoprotein having the amino acid sequence of SEQ ID NO: 1. 15. The method of claim 1, wherein the plurality of abatacept parameters comprises at least one abatacept parameter listed in Table 1 in addition to parameters 41 and 43. 16. The method of claim 1, wherein the processed drug product is structurally similar to abatacept so as to qualify as an abatacept drug product. 17. The method claim 1, wherein the plurality of the reference criterion shown in Table 1 is a product acceptance criterion. 18. The method of claim 1, wherein taking an alternative action comprises (a) reprocessing, (b) disposing of, or (c) rendering the test glycoprotein preparation unusable for commercial release by labeling or destroying it. 19. The method of claim 1, wherein the plurality of abatacept parameters further comprises at least one of parameters 35, 36, 37, 39, 40, and 42. 20. The method of claim 1, wherein the plurality of abatacept parameters further comprises at least two of parameters 35, 36, 37, 39, 40, and 42.

Details for Patent 10,450,361

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	12/23/2005		2039-10-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	07/29/2011		2039-10-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	06/07/2016		2039-10-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	03/30/2017		2039-10-23